150
Participants
Start Date
March 1, 2023
Primary Completion Date
October 31, 2025
Study Completion Date
March 31, 2026
EMB07
EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
RECRUITING
Peninsula and South Eastern Haematology and Oncology Group, Frankston
RECRUITING
One Clinical Research, Nedlands
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Affiliated Hospital of Hebei University, Baoding
RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Zhujiang Hospital of Southern Medical University, Guangzhou
RECRUITING
The Affiliated Tumour Hospital of Harbin Medical University, Harbin
RECRUITING
Shandong Cancer Hospital, Shandong
RECRUITING
Tianjin Medical University Cancer Institue & Hospital, Tianjin
Lead Sponsor
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
INDUSTRY